64 related articles for article (PubMed ID: 21168392)
41. Efficient synthesis of cyclic amidine-based fluorophores
Li G; Zhao M; Xie J; Yao Y; Mou L; Zhang X; Guo X; Sun W; Wang Z; Xu J; Xue J; Hu T; Zhang M; Li M; Hong L
Chem Sci; 2020 Mar; 11(14):3586-3591. PubMed ID: 34094046
[TBL] [Abstract][Full Text] [Related]
42. Neurokinin-1 Receptor Signaling Is Required for Efficient Ca
Morelli AE; Sumpter TL; Rojas-Canales DM; Bandyopadhyay M; Chen Z; Tkacheva O; Shufesky WJ; Wallace CT; Watkins SC; Berger A; Paige CJ; Falo LD; Larregina AT
Cell Rep; 2020 Mar; 30(10):3448-3465.e8. PubMed ID: 32160549
[TBL] [Abstract][Full Text] [Related]
43. The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.
Javid H; Mohammadi F; Zahiri E; Hashemy SI
J Physiol Biochem; 2019 Nov; 75(4):415-421. PubMed ID: 31372898
[TBL] [Abstract][Full Text] [Related]
44. β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G
Zhang YX; Li XF; Yuan GQ; Hu H; Song XY; Li JY; Miao XK; Zhou TX; Yang WL; Zhang XW; Mou LY; Wang R
J Biol Chem; 2017 May; 292(21):8933-8947. PubMed ID: 28341744
[TBL] [Abstract][Full Text] [Related]
45. Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP).
Mou L; Kang Y; Zhou Y; Zeng Q; Song H; Wang R
J Biol Chem; 2013 Jan; 288(1):306-18. PubMed ID: 23166329
[TBL] [Abstract][Full Text] [Related]
46. The role of the N-terminal and mid-region residues of substance P in regulating functional selectivity at the tachykinin NK1 receptor.
Perrine SA; Beard DJ; Young JK; Simmons MA
Eur J Pharmacol; 2008 Sep; 592(1-3):1-6. PubMed ID: 18634782
[TBL] [Abstract][Full Text] [Related]
47. Functional selectivity of NK1 receptor signaling: peptide agonists can preferentially produce receptor activation or desensitization.
Simmons MA
J Pharmacol Exp Ther; 2006 Nov; 319(2):907-13. PubMed ID: 16916996
[TBL] [Abstract][Full Text] [Related]
48. The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism.
van der Westhuizen ET; Werry TD; Sexton PM; Summers RJ
Mol Pharmacol; 2007 Jun; 71(6):1618-29. PubMed ID: 17351017
[TBL] [Abstract][Full Text] [Related]
49. Extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase, through nuclear factor-kappaB and activator protein-1, contribute to caerulein-induced expression of substance P and neurokinin-1 receptors in pancreatic acinar cells.
Koh YH; Tamizhselvi R; Bhatia M
J Pharmacol Exp Ther; 2010 Mar; 332(3):940-8. PubMed ID: 20007404
[TBL] [Abstract][Full Text] [Related]
50. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
El Zein N; Badran B; Sariban E
Cell Calcium; 2008 Mar; 43(3):270-84. PubMed ID: 17651798
[TBL] [Abstract][Full Text] [Related]
51. The N-terminal domain of human hemokinin-1 influences functional selectivity property for tachykinin receptor neurokinin-1.
Mou L; Xing Y; Kong Z; Zhou Y; Chen Z; Wang R
Biochem Pharmacol; 2011 Mar; 81(5):661-8. PubMed ID: 21168392
[TBL] [Abstract][Full Text] [Related]
52. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.
Quartara L; Maggi CA
Neuropeptides; 1997 Dec; 31(6):537-63. PubMed ID: 9574822
[TBL] [Abstract][Full Text] [Related]
53. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature.
Patacchini R; Lecci A; Holzer P; Maggi CA
Trends Pharmacol Sci; 2004 Jan; 25(1):1-3. PubMed ID: 14723970
[TBL] [Abstract][Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
